Current status and future of targeted peptide receptor radionuclide positron emission tomography imaging and therapy of gastroenteropancreatic-neuroendocrine tumors

被引：0

作者：

Neil Grey ^{[1
]}

Michael Silosky ^{[2
]}

Christopher H Lieu ^{[3
]}

Bennett B Chin ^{[2
]}

机构：

[1] Radiology-Nuclear Medicine, University of Colorado School of Medicine, Anschutz Medical Campus

[2] Medical Oncology, University of Colorado School of Medicine, Anschutz Medical Campus

[3] Department of Radiology, University of Colorado School of Medicine, Anschutz Medical Campus

来源：

World Journal of Gastroenterology | 2022年 / 17期

关键词：

D O I：

暂无

中图分类号：

R735 [消化系肿瘤];

学科分类号：

100214 ;

摘要：

Theranostics is the highly targeted molecular imaging and therapy of tumors.Targeted peptide receptor radionuclide therapy has taken the lead in demonstrating the safety and effectiveness of this molecular approach to treating cancers.Metastatic, well-differentiated gastroenteropancreatic neuroendocrine tumors may be most effectively imaged and treated with DOTATATE ligands. We review the current practice, safety, advantages, and limitations of DOTATATE based theranostics. Finally, we briefly describe the exciting new areas of development and future directions of gastroenteropancreatic neuroendocrine tumor theranostics.

引用

页码：1768 / 1780

页数：13

共 50 条

[21] Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors
Bodei, Lisa
Kidd, Mark
Prasad, Vikas
Modlin, Irvin M.
NEUROENDOCRINE TUMORS: A MULTIDISCIPLINARY APPROACH, 2015, 44 : 198 - 215
[22] Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors
Basu, Sandip
Parghane, Rahul, V
Kamaldeep
Chakrabarty, Sudipta
SEMINARS IN NUCLEAR MEDICINE, 2020, 50 (05) : 447 - 464
[23] Surgery enhances the effectiveness of peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumors Discussion
Demeure, Michael
Tobias, Joseph
Dickson, Paxton
Howe, Jim
Beck, Timothy
SURGERY, 2025, 177
[24] Indications of Peptide Receptor Radionuclide Therapy (PRRT) in Gastroenteropancreatic and Pulmonary Neuroendocrine Tumors: An Updated Review
Camus, Baptiste
Cottereau, Anne-Segolene
Palmieri, Lola-Jade
Dermine, Solene
Tenenbaum, Florence
Brezault, Catherine
Coriat, Romain
JOURNAL OF CLINICAL MEDICINE, 2021, 10 (06) : 1 - 18
[25] Peptide Receptor Radionuclide Nursing Roles in Managing Patients With Gastroenteropancreatic Neuroendocrine Tumors
Bennett, Bonita
Gardner, Linda
Ryan, Pamela
CLINICAL JOURNAL OF ONCOLOGY NURSING, 2024, 28 (01) : 79 - 87
[26] Peptide receptor radionuclide therapy of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): From literature to practice
Bournaud, C.
Kelly, A.
Hindie, E.
Tenenbaum, F.
Faivre-Chauvet, A.
Courbon, F.
Taieb, D.
Dierickx, L. O.
Coriat, R.
Ansquer, C.
MEDECINE NUCLEAIRE-IMAGERIE FONCTIONNELLE ET METABOLIQUE, 2017, 41 (01): : 42 - 54
[27] Laboratory, Clinical, and Survival Outcomes Associated With Peptide Receptor Radionuclide Therapy in Patients With Gastroenteropancreatic Neuroendocrine Tumors
Kipnis, Sarit T.
Hung, Matthew
Kumar, Shria
Heckert, Jason M.
Lee, Hwan
Bennett, Bonita
Soulen, Michael C.
Pryma, Daniel A.
Mankoff, David A.
Metz, David C.
Eads, Jennifer R.
Katona, Bryson W.
JAMA NETWORK OPEN, 2021, 4 (03)
[28] Peptide Receptor Radionuclide Therapy in the Treatment of Neuroendocrine Tumors
Kwekkeboom, Dik J.
Krenning, Eric P.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2016, 30 (01) : 179 - +
[29] Peptide Receptor Radionuclide Therapy for Advanced Neuroendocrine Tumors
Bodei, Lisa
Cremonesi, Marta
Kidd, Mark
Grana, Chiara M.
Severi, Stefano
Modlin, Irvin M.
Paganelli, Giovanni
THORACIC SURGERY CLINICS, 2014, 24 (03) : 333 - +
[30] Molecular Targeted Positron Emission Tomography Imaging and Radionuclide Therapy of Pancreatic Ductal Adenocarcinoma
Poels, Thomas T.
Vuijk, Floris A.
de Geus-Oei, Lioe-Fee
Vahrmeijer, Alexander L.
Oprea-Lager, Daniela E.
Swijnenburg, Rutger-Jan
CANCERS, 2021, 13 (24)

← 1 2 3 4 5 →